IL133126D0 - Oil in water vaccine compositions - Google Patents

Oil in water vaccine compositions

Info

Publication number
IL133126D0
IL133126D0 IL13312698A IL13312698A IL133126D0 IL 133126 D0 IL133126 D0 IL 133126D0 IL 13312698 A IL13312698 A IL 13312698A IL 13312698 A IL13312698 A IL 13312698A IL 133126 D0 IL133126 D0 IL 133126D0
Authority
IL
Israel
Prior art keywords
oil
vaccine compositions
water vaccine
water
compositions
Prior art date
Application number
IL13312698A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9711990.3A priority Critical patent/GB9711990D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Priority to PCT/EP1998/003479 priority patent/WO1998056414A1/fr
Publication of IL133126D0 publication Critical patent/IL133126D0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
IL13312698A 1997-06-11 1998-06-03 Oil in water vaccine compositions IL133126D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine
PCT/EP1998/003479 WO1998056414A1 (fr) 1997-06-11 1998-06-03 Compositions de vaccins huile-dans-eau

Publications (1)

Publication Number Publication Date
IL133126D0 true IL133126D0 (en) 2001-03-19

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13312698A IL133126D0 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions

Country Status (17)

Country Link
EP (1) EP0999852A1 (fr)
JP (1) JP2002504106A (fr)
KR (1) KR20010013644A (fr)
CN (1) CN1260723A (fr)
AR (1) AR012959A1 (fr)
AU (1) AU728759B2 (fr)
BR (1) BR9810614A (fr)
CA (1) CA2293444A1 (fr)
CO (1) CO4940401A1 (fr)
GB (1) GB9711990D0 (fr)
HU (1) HU0004001A3 (fr)
IL (1) IL133126D0 (fr)
NO (1) NO996133L (fr)
PL (1) PL337488A1 (fr)
TR (1) TR199903048T2 (fr)
WO (1) WO1998056414A1 (fr)
ZA (1) ZA9804969B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CA2370697C (fr) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Vaccins
AT534401T (de) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
AT516046T (de) * 1999-05-13 2011-07-15 Wyeth Corp Adjuvans kombinationsformulierungen
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
EP1741782B1 (fr) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Polypeptides immunogéniques codés par des minigènes mage et leurs utilisations
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20040241094A1 (en) * 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
CA2502268A1 (fr) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methodes de vaccination contre le paludisme
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
CA2565500A1 (fr) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CA2601022A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
HUE041979T2 (hu) 2005-12-22 2019-06-28 Glaxosmithkline Biologicals Sa Pneumococcus poliszacharid-konjugátum oltóanyag
AU2007233705B2 (en) 2006-03-30 2010-12-23 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
EA200900024A1 (ru) 2006-07-17 2009-06-30 Глаксосмитклайн Байолоджикалс С.А. Противогриппозная вакцина
NZ574239A (en) 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AT555808T (de) 2006-09-26 2012-05-15 Infectious Disease Res Inst Impfstoffzusammensetzung mit einem synthetischen adjuvans
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
AU2007318026B2 (en) 2006-11-03 2013-04-18 Merck Sharp & Dohme (Holdings) Pty Ltd Canine Lyme disease vaccine
PT2137210T (pt) 2007-03-02 2017-01-09 Glaxosmithkline Biologicals Sa Novos métodos e composições
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
BRPI0815199A2 (pt) 2007-08-13 2015-03-31 Glaxosmithkline Biolog Sa Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
EP2293813A4 (fr) 2008-05-23 2012-07-11 Univ Michigan Vaccins à nanoémulsion
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036945A2 (fr) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Compositions thérapeutiques du type nano-émulsion et procédés pour les utiliser
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
WO2010092479A2 (fr) 2009-02-10 2010-08-19 Novartis Ag Vaccins contre la grippe comportant des quantités réduites de squalène
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
CA2764374A1 (fr) 2009-06-05 2010-12-09 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
WO2010148111A1 (fr) 2009-06-16 2010-12-23 The Regents Of The University Of Michigan Vaccins en nano-émulsion
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EA201390452A1 (ru) 2010-09-27 2013-11-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
BR112013025799A2 (pt) 2011-04-08 2016-12-20 Immune Design Corp método para induzir uma resposta imune em um sujeito, e, preparação
US20140348844A1 (en) 2011-09-16 2014-11-27 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013083753A2 (fr) 2011-12-07 2013-06-13 Institut Pasteur Identification d'un virus porcin de type paréchovirus et applications
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Institute Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
CA2874923A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Peptides issus de proteines virales pour l'utilisation en tant qu'immunogenes et reactifs de dosage
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールSanofipasteur ワクチン組成物
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
BR112015009229A2 (pt) 2012-10-24 2017-11-14 Platelet Targeted Therapeutics Llc composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
WO2014083194A1 (fr) 2012-11-30 2014-06-05 Sanofi Pasteur Procédés d'induction d'anticorps
MX2015014431A (es) 2013-04-18 2016-06-02 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3063171B1 (fr) 2013-11-01 2019-07-24 University Of Oslo Variants d'albumine et utilisations de ceux-ci
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2015071769A2 (fr) 2013-11-13 2015-05-21 University Of Oslo Vésicules de membrane externe et utilisation associées
EP3069138B1 (fr) 2013-11-15 2019-01-09 Oslo Universitetssykehus HF Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
EA201691028A1 (ru) 2013-11-20 2017-01-30 Ла Хойя Инститьют Фор Эллерджи Энд Иммьюнолоджи Пан-иммуногены пыльцы, способы и применение для модуляции иммунного ответа
WO2015077442A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
CR20160369A (es) 2014-01-21 2016-10-05 Immune Desing Corp Composiciones para uso en el tratamiento de afecciones alérgicas
WO2015131053A1 (fr) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
CA3011887A1 (fr) 2016-03-14 2017-09-21 Stian FOSS Immunoglobulines genetiquement transformees ayant une liaison a fcrn alteree
EP3471761A2 (fr) 2016-06-21 2019-04-24 University Of Oslo Fragments de vaccin de liaison à hla et leurs utilisations
JP2019528072A (ja) 2016-08-23 2019-10-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原がインバリアント鎖(cd74)の小断片と連結された融合ペプチド
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018232257A1 (fr) 2017-06-15 2018-12-20 Infectious Disease Research Institute Supports lipidiques nanostructurés et émulsions stables et leurs utilisations
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
WO2019048936A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules vaccinales
WO2019090233A2 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Procédé pour inactiver le virus zika et pour déterminer la complétude de l'inactivation
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
AU8336598A (en) 1998-12-30
CA2293444A1 (fr) 1998-12-17
ZA9804969B (en) 1999-12-09
NO996133L (no) 2000-01-26
CN1260723A (zh) 2000-07-19
PL337488A1 (en) 2000-08-28
HU0004001A2 (en) 2001-03-28
AU728759B2 (en) 2001-01-18
TR199903048T2 (xx) 2000-08-21
EP0999852A1 (fr) 2000-05-17
NO996133D0 (no) 1999-12-10
AR012959A1 (es) 2000-11-22
HU0004001A3 (en) 2001-07-30
JP2002504106A (ja) 2002-02-05
KR20010013644A (ko) 2001-02-26
CO4940401A1 (es) 2000-07-24
GB9711990D0 (en) 1997-08-06
WO1998056414A1 (fr) 1998-12-17
BR9810614A (pt) 2000-09-12

Similar Documents

Publication Publication Date Title
GB2308846B (en) Water absorbing compositions
DE69834346D1 (en) Proteinexpression in baculovirus-vektor expressionsystemen
DE69927412D1 (en) Phosphitadditive in polyolefinen
DK1298194T3 (da) Staniolholdige sammensætninger
AU1145699A (en) Oil in water emulsions containing saponins
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
HU0101619A3 (en) Adjuvant compositions
NZ333145A (en) Natural oil extracts as antimicrobial compositions
HU0101696A3 (en) Shampoo composition
PL337488A1 (en) Oil-in-water type compositions for vaccines
EG20881A (en) Cleaning compositions
PL336840A1 (en) Hair-care composition
GB0011343D0 (en) Improvements in or relating to downhole tools
IL128683D0 (en) Novel water soluble working fluids
GB9804720D0 (en) Shampoo compositions
AP200001874A0 (en) Cellecoxib compositions
GB9917982D0 (en) Compositions
GB9804725D0 (en) Shampoo compositions
HK1014872A1 (en) Improvements in or relating to contrast agents
HU0000282A3 (en) Improvements in or relating to contrast agents
PL338451A1 (en) Cosmetic compositions
ZA9808858B (en) Improvements in or relating to organic compositions
GB9700140D0 (en) Improvements in or relating to organic compositions
PT938345E (pt) Composicao a base de agua
ZA9708868B (en) Vaccine composition